Find out the latest with BOPA, Oncology, and upcoming events
NICE is looking for a pharmacist and a pathologist with a specialist interest and current experience in lung cancer to join the lung cancer guideline committee. Closing date: 5pm, Wednesday 26…
We are consulting on changes to our constitution. The BOPA committee have discussed and agreed updates to the constitution to reflect current working practices Please see our documents – consultations page…
BOPA Symposium abstract submissions are now closed.
Extended BOPA abstract submission date: 11am Monday 19 June Click HERE to submit your abstract
BOPA is building links with the British Biosimilars Association BBA. The BOPA committee is keen to support our members dealing with the work of managing the introduction of biosimilars, and so…
Time is ticking away and its now time to get your research, audit or service evaluation abstract submitted for the 2017 Symposium! The deadline for submission is next week –…
To support BOPA members managing the introduction of biosimilar rituximab, a paper has been published on the members documents section of website which BOPA members can use in their own…
BOPA is working in partnership with university of Liverpool who are developing a web based anticancer drug interactions resource. Please see advert below for editorial assistant. Grade 6 Editorial Assistant…
Please click HERE to see the flyer for the evening meeting in Manchester from the Cancer Vanguard. If you would like to attend this session, please email [email protected]
Regimen-specific consent forms for the following tumour groups have been published on the Cancer Research UK website: Lung cancer – 28 forms Supportive medicines – 2 forms Colorectal cancer –…
REGISTRATION IS NOW OPEN Friday 6 – Sunday 8 October 2017 Scottish Event Campus (SEC), Glasgow Special Anniversary Year Offer of 50% Discount for BOPA Members Click HERE to register
For the last two years BOPA has successfully worked alongside Amgen to deliver Myeloma study days featuring the excellent Elaine Vickers who can really bring the science of novel agents…
